Investor Overview

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.

We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.

Stock Quote

Recent News

Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today
Toggle Summary Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update 
- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 - QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 - Lebrikizumab Phase 2b enrollment expected to be completed by end of 2018 MENLO PARK, Calif. , Aug.
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced
Toggle Summary Dermira Receives FDA Approval for Qbrexza™ (glycopyrronium) Cloth to Treat Primary Axillary Hyperhidrosis
Qbrexza is the first FDA -approved, once-daily, topical prescription treatment indicated for people with primary axillary hyperhidrosis, also known as excessive underarm sweating The chronic, medical skin condition is estimated to affect nearly 10 million people in the U.S.
Toggle Summary Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MENLO PARK, Calif. , June 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced

Upcoming Events

There are currently no events to display.

Copyright Nasdaq. Minimum 15 minutes delayed.